Santhera Pharmaceuticals Holding AG Overview
Pro stress-test →Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. The company targets orphan indications including Duchenne muscular dystrophy (DMD), cystic fibrosis (CF), and other rare genetic disorders with limited treatment options.
Strategic Profile
Pro stress-test →Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, currently investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases. The company derives the majority of revenue from Europe and has secured financing to reach cash flow break-even.
Competitive Landscape
Pro stress-test →Santhera competes in the rare neuromuscular disease space against companies developing DMD therapeutics and CF treatments. Key competitors include gene therapy platforms (Edgewise Therapeutics and others in rare disease), though vamorolone's novel steroid mechanism offers differentiation from existing corticosteroid standard of care and emerging gene therapies.
Industry Context
Santhera Pharmaceuticals Holding AG operates in Specialty Pharmaceuticals / Biotech (Rare Neuromuscular and Pulmonary Diseases).
Key facts
Founded: 1998 · Headquarters: Pratteln, Switzerland · Employees: 85 · Revenue: $56.5M · Market cap: $305M